KARD.US Kardigan, Inc. Common Stock
- Market cap
- USD 1.29B
- P/E
- -
- P/B
- 2.10x
- ROE
- -53.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KARD.US undervalued?
Graham numberThe Graham number of Kardigan, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kardigan, Inc. Common Stock fundamental analysis
No fundamental analysis for Kardigan, Inc. Common Stock yet.
Kardigan, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kardigan, Inc. Common Stock
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimi…
Full company profileKardigan, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kardigan, Inc. Common Stock annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | - |
| Operating Income | -96.7M | -202M | -294M |
| EBITDA | -96.3M | -196M | -259M |
| Net Income | -88.7M | -192M | -308M |
| EPS | -0.99 | -3.20 | -3.34 |
| Balance Sheet | |||
| Total Assets | 63.5M | 391M | 649M |
| Total Liabilities | 147M | 641M | 76.7M |
| Shareholders' Equity | -83.2M | -250M | 573M |
| Cash & Short-term Investments | 49.4M | 335M | 472M |
| Total Debt | - | 13.8M | 12.7M |
| Cash Flow | |||
| Operating Cash Flow | -18.8M | -151M | -223M |
| Capital Expenditure | 36.4M | 6.64M | 6.01M |
| Free Cash Flow | -55.2M | -158M | -226M |
| Ratios | |||
| ROE | - | - | -53.8% |
| ROA | -139.6% | -49.1% | -47.4% |
| Debt to Equity | - | - | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kardigan, Inc. Common Stock dividends
Kardigan, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Kardigan, Inc. Common Stock
- Insiders 16.36%
- Institutions 83.64%
- Public & others 0.00%
- Shares outstanding 93.6M
- Free float 51.9M
Top funds holding KARD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 3.53M | 3.77% | +0.62% | Sep 2026 |
| Fidelity Contrafund | 1.49M | 1.59% | +18.86% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 908K | 0.97% | +860.65% | Sep 2026 |
| JPMorgan Small Cap Growth A | 806K | 0.86% | -0.61% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 782K | 0.84% | -42.05% | Sep 2026 |
| iShares Russell 2000 ETF | 716K | 0.77% | 0.00% | Oct 2026 |
| T. Rowe Price Small-Cap Value | 615K | 0.66% | 0.00% | Sep 2026 |
| AB Small Cap Growth A | 602K | 0.64% | -2.51% | Sep 2026 |
| Fidelity Growth Company Fund | 598K | 0.64% | +1.06% | Aug 2026 |
| MFS New Discovery I | 474K | 0.51% | 0.00% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 420K | 0.45% | +5.50% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 410K | 0.44% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 376K | 0.40% | -11.03% | Sep 2026 |
| Fidelity Blue Chip Growth | 352K | 0.38% | 0.00% | Sep 2026 |
| Fidelity Contrafund K6 | 309K | 0.33% | +20.20% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 300K | 0.32% | 0.00% | Jun 2026 |
| JPMorgan Small Cap Blend A | 256K | 0.27% | -1.63% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 255K | 0.27% | 0.00% | Sep 2026 |
| Principal SmallCap Growth I Instl | 192K | 0.21% | +1.09% | Sep 2026 |
| BNY Mellon Sm/Md Cp Gr I | 169K | 0.18% | -1.86% | Sep 2026 |
Top institutions holding KARD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SCHF (GPE), LLC | 16.9M | 18.08% | 0.00% | Sep 2026 |
| FMR Inc | 8.91M | 9.52% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 8.20M | 8.77% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 4.21M | 4.50% | 0.00% | Jun 2026 |
| Capital Research Global Investors | 3.62M | 3.87% | +0.53% | Sep 2026 |
| JPMorgan Chase & Co | 1.79M | 1.91% | 0.00% | Jun 2026 |
| AllianceBernstein L.P. | 1.53M | 1.64% | 0.00% | Jun 2026 |
| Liberty Mutual Group Asset Management Inc. | 1.20M | 1.28% | 0.00% | Jun 2026 |
| Jennison Associates LLC | 904K | 0.97% | 0.00% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 900K | 0.96% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 750K | 0.80% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 659K | 0.70% | 0.00% | Jun 2026 |
| Massachusetts Financial Services Company | 650K | 0.69% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 645K | 0.69% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 600K | 0.64% | 0.00% | Jun 2026 |
| Woodline Partners LP | 414K | 0.44% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 400K | 0.43% | 0.00% | Jun 2026 |
| Suvretta Capital Management, LLC | 400K | 0.43% | 0.00% | Jun 2026 |
| Bank of New York Mellon Corp | 378K | 0.40% | 0.00% | Jun 2026 |
| Catalio Capital Management, LP | 313K | 0.33% | 0.00% | Jun 2026 |
Kardigan, Inc. Common Stock company profile
- Company name
- Kardigan, Inc. Common Stock
- Ticker
- KARD.US
- Exchange
- USA Stocks
- Listed since
- Jun 18, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 241
- Fiscal year end
- December
- Address
- 506 Carnegie Center Drive, Princeton, NJ, United States, 08540
- Phone
- (415) 573-3220
- Website
- kardigan.bio
About Kardigan, Inc. Common Stock
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.
Kardigan, Inc. Common Stock management
10- Mr. Tassos Anastasios E. Gianakakos M.Sc., MBACo-Founder, President, CEO & Chairman · born 1973
- Dr. Jay Edelberg M.D., Ph.D.Co-founder & Chief Medical Officer · born 1964
- Ms. Brianne PuglisiChief Financial Officer · born 1987
- Dr. Bob McDowell Ph.D.Co-founder & Scientific Advisor
- Dr. Leslie A. Leinwand Ph.D.Co-Founder
- Dr. Elizabeth McNally M.D., Ph.D.Co-Founder · born 1961
- Mr. Donald Mackenzie Ph.D.Chief Technical Operations Officer
- Mr. Clayton RobertsonVice President of Investor Relations
- Mr. John B. Moriarty Jr., ESQ., J.D.Chief Legal Officer & Corporate Secretary · born 1968
- Ms. Emily FaucetteChief Communications Officer